FORT LEE, N.J., March 31 /PRNewswire-FirstCall/ -- Alpharma Inc. announced today that it completed its previously announced sale of ParMed Pharmaceuticals, Inc. (“ParMed”), its generic pharmaceutical telemarketing distribution business, to Cardinal Health, Inc. , for $40.1 million in cash.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world’s leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other significant potential risks and uncertainties not discussed herein may be found in the Company’s filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2005.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc.
CONTACT: Kathleen Makrakis, VP Investor Relations of Alpharma,+1-201-228-5085, kathleen.makrakis@alpharma.com
Web site: http://www.alpharma.com/
